Results 61 to 70 of about 775,328 (297)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors

Cancers, 2021
Simple Summary Minimal residual disease (MRD) represents a status of the disease which is assumed to still be present in the body until it is clinically observed by radiology.
L. Larribère, U. Martens
semanticscholar   +1 more source

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study

Haematologica, 2016
Quantification of minimal residual disease may guide therapeutic strategies in mantle cell lymphoma. While multiparameter flow cytometry is used for diagnosis, the gold standard method for minimal residual disease analysis is real-time quantitative ...
Morgane Cheminant, Coralie Derrieux, Aurore Touzart, Stéphanie Schmit, Adrien Grenier, Amélie Trinquand, Marie-Hélène Delfau-Larue, Ludovic Lhermitte, Catherine Thieblemont, Vincent Ribrag, Stéphane Cheze, Laurence Sanhes, Fabrice Jardin, François Lefrère, Richard Delarue, Eva Hoster, Martin Dreyling, Vahid Asnafi, Olivier Hermine, Elizabeth Macintyre   +19 more
doaj   +1 more source

Cellular dormancy in minimal residual disease following targeted therapy

Breast Cancer Research, 2021
Background Breast cancer mortality is principally due to tumor recurrence, which can occur following extended periods of clinical remission that may last decades.
Jason R. Ruth, Dhruv K. Pant, Tien-chi Pan, Hans E. Seidel, Sanjeethan C. Baksh, Blaine A. Keister, Rita Singh, Christopher J. Sterner, Suzanne J. Bakewell, Susan E. Moody, George K. Belka, Lewis A. Chodosh   +11 more
doaj   +1 more source

In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice. [PDF]

, 2012
Xenograft mouse models represent helpful tools for preclinical studies on human tumors. For modeling the complexity of the human disease, primary tumor cells are by far superior to established cell lines.
Brentjens, Renier J., Castro Alves, Catarina, Ehrhardt, Harald, Farkasova, Katarina, Groiss, Volker, Horstmann, Martin, Jeremias, Irmela, Ogris, Manfred, Quintanilla-Martinez, Leticia, Schneider, Katja, Terziyska, Nadia, Wagner, Ernst, zur Stadt, Udo   +12 more
core   +3 more sources

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact

Cancers, 2021
Simple Summary The field of liquid biopsy is rapidly evolving. Techniques that improve accuracy are constantly being developed, and clinicians increasingly use liquid biopsy as a tool to guide their clinical practice.
N. Honoré, R. Galot, C. van Marcke, N. Limaye, J. Machiels   +4 more
semanticscholar   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia [PDF]

International Journal of Hematology-Oncology and Stem Cell Research, 2005
Background: Induction Chemotherapy for Acute Lymphoblastic Leukemia achieves complete remis¬sion in over 90% of children. It is apparent therefore that many patients in clinical remission and with¬out residual disease detectable by conventional light ...
P Vossough, M Faranoush, Z Emami, Gh Bahoush, Kh Arjmandi, Sh Ansari, M Alebouyeh, E Shahgholi, A.A Hedayatiasl   +8 more
doaj   +1 more source

Accurate sample assignment in a multiplexed, ultrasensitive, high-throughput sequencing assay for minimal residual disease [PDF]

, 2016
High-throughput sequencing (HTS) (next-generation sequencing) of the rearranged Ig and T-cell receptor genes promises to be less expensive and more sensitive than current methods of monitoring minimal residual disease (MRD) in patients with acute ...
Bartram, J, Brooks, T, Goulden, N, Hancock, J, Hubank, M, Moppett, J, Mountjoy, E, Williamson, H, Wright, G   +8 more
core   +1 more source

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

Clinical Cancer Research, 2021
Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients.
T. Henriksen, N. Tarazona, A. Frydendahl, T. Reinert, F. Gimeno-Valiente, J. Carbonell-Asins, Shruti Sharma, D. Renner, D. Hafez, D. Roda, M. Huerta, S. Roselló, A. H. Madsen, U. S. Løve, P. Andersen, O. Thorlacius-Ussing, L. Iversen, K. A. Gotschalck, H. Sethi, A. Aleshin, A. Cervantes, C. Andersen   +21 more
semanticscholar   +1 more source

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

International Journal of Molecular Sciences, 2020
Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further ...
A. Kruse, Nour Abdel-Azim, Hye Na Kim, Y. Ruan, Valerie Phan, H. Ogana, William C. C. Wang, Rachel M. Lee, E. Gang, S. Khazal, Yong-Mi Kim   +10 more
semanticscholar   +1 more source